ALL patients with certain gene regulation patterns may be less likely to respond to CAR T-cell therapy

Wugen launches phase II study of CD7-targeted CAR T for r/r T-ALL or T-ALL/LBL

Wugen Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, announced it will initiate a phase II study in the first quarter of 2025 for the company’s potential first-in-class, investigational, anti-CD7 CAR T-cell therapy, WU-CART-007, in patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.

November 15, 2024

Vol.50 No.43

In Brief

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Tampa General Hospital and Mass General Brigham announced a strengthening of their affiliation with the development of new programs and services, including a bone marrow transplant program and CAR T therapy program, at TGH.

September 20, 2024

Vol.50 No.35

Clinical

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

Clinical Roundup

Five-year study identifies long-term effects of axi-cel CAR T treatment

Axicabtagene ciloleucel, commonly known as axi-cel, is an immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma.

August 09, 2024

Vol.50 No.32

Clinical Roundup

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

A new study details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the clinical-stage cell therapy company Vittoria Biotherapeutics’ proprietary Senza5TM platform.

July 26, 2024

Vol.50 No.30

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

July 12, 2024

Vol.50 No.28

By Matthew Bin Han Ong

ALL patients with certain gene regulation patterns may be less likely to respond to CAR T-cell therapy

YOU MAY BE INTERESTED IN

Wugen launches phase II study of CD7-targeted CAR T for r/r T-ALL or T-ALL/LBL

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Five-year study identifies long-term effects of axi-cel CAR T treatment

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

Renew today!

Subscriber content

Login

ALL patients with certain gene regulation patterns may be less likely to respond to CAR T-cell therapy

YOU MAY BE INTERESTED IN

Wugen launches phase II study of CD7-targeted CAR T for r/r T-ALL or T-ALL/LBL

Tampa General, Mass General Brigham strengthen relationship through BMT, CAR T collaboration

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Five-year study identifies long-term effects of axi-cel CAR T treatment

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Infections are a major cause of death in patients treated with CAR T-cell therapyMeta-analysis focused on causes of death, excluding relapse, recurrence

Login

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence